Project Oncology®

Guest: Everett E. Vokes, MD

In this Grand Rounds recorded live at ASCO, Dr. Vokes introduces the concept of T-cell blockade and Checkpoint Inhibition as rationale for considering use of anti-PD-1 anti-CTLA-4 agents in the management of non-small cell lung cancer (NSCLC). Also discussed will be data reflective of the use of tumor biomarkers when selecting treatment strategies for patients with NSCLC, specifically those with elevated expression of PD-L1.

Guest: Richard S. Finn, MD

Hormone receptor–positive (HR+) disease is the most commonly diagnosed subset of breast cancer. Although endocrine therapy is the cornerstone of treatment for patients with HR+ advanced breast cancer, not all cases respond to first-line endocrine therapy, and disease that does respond eventually relapses. Because endocrine therapy–resistant HR+ disease is a significant problem, new therapeutic strategies to enhance the efficacy of endocrine therapy are being studied. Several CDK 4/6 inhibitors have shown promising results in the treatment of breast cancer, particularly HR+, HER2-negative metastatic disease. However, clinicians may not be familiar with the mechanisms of CDK 4/6 inhibition and why it is relevant in the treatment of breast cancer. Similarly, clinicians may not be familiar with the efficacy and safety of approved and emerging CDK 4/6 inhibitors in the treatment of breast cancer that is resistant to endocrine therapy. This Virtual Grand Rounds initiative is designed to close these knowledge gaps and provide clinicians with up-to-date information about approved and emerging therapies so that they can make informed choices regarding the management of breast cancer. Topics covered in this activity include the development of endocrine resistance in breast cancer; the significance of CDK inhibition; and the relevant clinical trial data about ...

Host: Matt Birnholz, MD

Guest: Everett E. Vokes, MD

Dr. Birnholz and Dr. Vokes will be discussing some of the exciting new data presented at ASCO 2016 on the management of non-small cell lung cancer. Since the recording of this interview, pembrolizumab was approved by the FDA on October 24, 2016 for use in Non-small Cell Lung Cancer.

Guest: Warner K. Huh, MD

Guest: Thomas C. Wright, Jr., MD

HPV experts, Drs. Warner Huh and Tom Wright discuss the potential of extended HPV genotype testing in high-risk HPV screening for cervical cancer, and the impact that this may have on the current cervical cancer algorithms.

Host: Matt Birnholz, MD

Cannabis is gaining increased acceptance within the medical community for pain relief and other supportive care applications. But for oncology specialties, the use of cannabis may additionally extend into therapeutic purposes for patients.

From the floors of the A4M Conference in Las Vegas, Dr. Matt Birnholz speaks with Constance Finley, Founder and CEO of Constance Therapeutics, a California-based cannabis collective. The two discuss cannabis and cannabis oil applications for cancer patients, and their potential therapeutic effects.

Host: Renée Simone Yolanda Allen, MD, MHSc., FACOG

From the American Cancer Society, ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. A woman's risk of getting ovarian cancer during her lifetime is about 1 in 75. Her lifetime chance of dying from ovarian cancer is about 1 in 100. Host Dr. Renee Allen is joined by Dr. Evelyn Reynolds to discuss critical updates in ovarian cancer, specifically dispelling the myth about ovarian cancer being a "silent killer." Dr. Reynolds an Associate Professor and Division Director of Gynecologic Oncology at the Morehouse School of Medicine. She is board-certified in General Obstetrics and Gynecology and also Gynecologic Oncology.

Host: Renée Simone Yolanda Allen, MD, MHSc., FACOG

What is the role and importance of the Ob-Gyn Oncologist, especially for women diagnosed with pelvic cancers? What are some barriers patients face in seeing an Ob-Gyn Oncoloogist? And how can clinicians better partner with this group of specialists? In this episode, host Dr. Renee Allen explores answers to these questions with guest expert Dr. Evelyn Reynolds, board certified physician in both General Obstetrics & Gynecology and Gynecologic Oncology. She is also an Associate Professor and Division Director of Gynecologic Oncology at the Morehouse School of Medicine.

Host: Matt Birnholz, MD

Guest: Edward R. Sauter, MD, PhD, MHA

In the clinical arena, discussions on breast cancer prevention and treatment often center on what is considered most "cutting edge," from genetic mechanisms of disease to new combination pharmacotherapies to breast-conserving surgical innovations. But another field of study, targeting the potential roles of nutrition in breast cancer risk, remains commonly neglected by the medical community. What parts do nutritional choices and habits play in breast cancer development, and how can clinicians make better risk assessments given this information?

Dr. Edward Sauter, Professor of Surgery and Director of the Cancer Treatment and Prevention Center at the University of Texas Health Sciences Center, joins Dr. Matt Birnholz to discuss emerging connections between nutrition and breast cancer.

Host: Matt Birnholz, MD

Guest: Edward R. Sauter, MD, PhD, MHA

In the clinical arena, discussions on breast cancer prevention and treatment often center on what is considered most "cutting edge," from genetic mechanisms of disease to new combination pharmacotherapies to breast-conserving surgical innovations. But another field of study, targeting the potential roles of nutrition in breast cancer risk, remains commonly neglected by the medical community. What parts do nutritional choices and habits play in breast cancer development, and how can clinicians make better risk assessments given this information?

Dr. Edward Sauter, Professor of Surgery and Director of the Cancer Treatment and Prevention Center at the University of Texas Health Sciences Center, joins Dr. Matt Birnholz to discuss emerging connections between nutrition and breast cancer.